Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus pulsed pegylated interferon alpha-2b plus nucleos(t)ide analogs in chronic hepatitis B
ChiCTR2300072916Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jun 2023
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: HBsAg negative rate at 96 weeks and HBsAb seroconversion rate at 96 weeks. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2300072916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072916.